Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1830P - Association of body composition measured by bioelectrical impedance analysis and hematologic adverse events in early-stage breast cancer patients receiving chemotherapy

Date

17 Sep 2020

Session

E-Poster Display

Topics

Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

Jirawat Thanestada

Citation

Annals of Oncology (2020) 31 (suppl_4): S988-S1017. 10.1016/annonc/annonc291

Authors

J. Thanestada1, V. Srinonprasert2, A. Nimmannit3, K. Korphaisarn1, P. Pramyothin4, C. Akewanlop1

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 2 Division Of Geriatrics, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 3 Office For Research And Development, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 4 Division Of Nutrition, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1830P

Background

The low muscular component is associated with diminished cancer treatment outcomes and increased toxicities. Various studies focused on advanced measurement techniques using dual energy X-ray absorptiometry (DEXA) scan or CT-based analysis, while study on bioelectrical impedance analysis (BIA) was limited. This study examined the association of body composition measured by BIA on the hematologic adverse events in early-stage breast cancer (EBC) patients receiving chemotherapy.

Methods

A total of 144 female patients with EBC were enrolled in this study. Body weight (BW) and fat-free mass (FFM) were measured by BIA analyzer before starting of the first cycle of chemotherapy. BW and FFM were converted into body mass index (BMI) and fat-free mass index (FFMI) by dividing with squared height (in meter) of the patient. The association between FFMI and composite adverse events (CAE), including grade 4 neutropenia, febrile neutropenia and relative dose intensity < 85% were explored.

Results

Of the 144 patients, CAE occurred in 85 patients (59%), and point biserial correlation showed an inverse correlation between FFMI and CAE. Per the international consensus, none of these patients matched with sarcopenic criteria (FFMI < 11.4 kg/m2). AUC analysis revealed that FFMI of < 14.85 kg/m2 should be the cut point for low FFMI. Using this cut point, 85 patients were classified as low FFMI, and 62 patients (72.9%) had CAE with a notable relative risk (RR) of 1.86 (p < 0.001). After adjusting for other factors, low FFMI was significantly associated with a high CAE rate (adjusted odds ratio (OR) 4.562, p < 0.001).

Conclusions

A low FFMI was significantly correlated with increased risk of severe neutropenia and decreased relative dose intensity in patients with EBC receiving chemotherapy. FFMI measured by BIA is a useful tool to detect patient-at-risk in this situation, so preventive measures could be considered to improve treatment outcomes.

Clinical trial identification

TCTR20190702004.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.